The United States could soon have another tool in the fight against respiratory syncytial virus, an illness that’s the No. 1 ...

As winter settles over Australia, it's not just the drop in temperature we notice—there's also a sharp rise in respiratory ...

Meanwhile, Sanofi has pointed to Beyfortus’ 75% reduction in the incidence of MALRI versus Enflosia’s figure of 60%. The ...

The announcement comes as part of WHO’s broader effort to reduce child mortality, particularly in low- and middle-income ...

Respiratory syncytial virus (RSV) causes millions of childhood illnesses yearly, particularly in poorer countries. On 30 May 2025, the World Health Organisation issued its first global guidance ...

June 2, 2025 - Last Friday, the World Health Organization (WHO) published its first-ever position paper on immunization ...

Enflonsia is the first FDA-approved respiratory syncytial virus (RSV) preventative for infants, regardless of weight, according to the news release.

French drugmaker Sanofi SA (NASDAQ:SNY) on Monday said it is shipping Beyfortus (nirsevimab) starting in early Q3 to ensure ...

Merck & Co – known as MSD outside the US and Canada – has announced that its respiratory syncytial virus (RSV) preventive ...

RSV causes about 100,000 deaths and more than 3.6 million hospitalisations in children under the age of 5 worldwide ...